DK1764361T3 - Krystal af 1,2-dihydropyridinforbindelse og fremgangsmåde til fremstilling heraf - Google Patents

Krystal af 1,2-dihydropyridinforbindelse og fremgangsmåde til fremstilling heraf

Info

Publication number
DK1764361T3
DK1764361T3 DK05758232.2T DK05758232T DK1764361T3 DK 1764361 T3 DK1764361 T3 DK 1764361T3 DK 05758232 T DK05758232 T DK 05758232T DK 1764361 T3 DK1764361 T3 DK 1764361T3
Authority
DK
Denmark
Prior art keywords
crystal
preparation
dihydropyridine compound
dihydropyridine
compound
Prior art date
Application number
DK05758232.2T
Other languages
Danish (da)
English (en)
Inventor
Itaru Arimoto
Satoshi Nagato
Yukiko Sugaya
Yoshio Urawa
Koichi Ito
Hiroyuki Naka
Takao Omae
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35782900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1764361(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of DK1764361T3 publication Critical patent/DK1764361T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
DK05758232.2T 2004-07-06 2005-07-05 Krystal af 1,2-dihydropyridinforbindelse og fremgangsmåde til fremstilling heraf DK1764361T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004198709 2004-07-06
PCT/JP2005/012388 WO2006004107A1 (ja) 2004-07-06 2005-07-05 1,2-ジヒドロピリジン化合物の結晶およびその製造方法

Publications (1)

Publication Number Publication Date
DK1764361T3 true DK1764361T3 (da) 2013-05-06

Family

ID=35782900

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05758232.2T DK1764361T3 (da) 2004-07-06 2005-07-05 Krystal af 1,2-dihydropyridinforbindelse og fremgangsmåde til fremstilling heraf

Country Status (28)

Country Link
US (3) US8304548B2 (https=)
EP (3) EP1772450B1 (https=)
JP (3) JP5030206B2 (https=)
KR (2) KR101187218B1 (https=)
CN (7) CN101914057B (https=)
AT (1) ATE547405T1 (https=)
AU (2) AU2005258385B2 (https=)
BR (1) BRPI0510254B8 (https=)
CA (2) CA2561829C (https=)
CY (1) CY1114313T1 (https=)
DK (1) DK1764361T3 (https=)
ES (1) ES2404697T3 (https=)
HR (1) HRP20130363T1 (https=)
IL (2) IL180024A (https=)
JO (1) JO2832B1 (https=)
ME (1) ME01520B (https=)
MX (1) MXPA06014458A (https=)
MY (1) MY148809A (https=)
NO (1) NO339101B1 (https=)
NZ (1) NZ550720A (https=)
PL (2) PL1772450T3 (https=)
PT (1) PT1764361E (https=)
RS (1) RS52752B (https=)
RU (1) RU2323930C1 (https=)
SI (2) SI1764361T1 (https=)
TW (1) TW200606144A (https=)
WO (2) WO2006004100A1 (https=)
ZA (1) ZA200609274B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100358872C (zh) 2003-11-14 2008-01-02 上海睿星基因技术有限公司 吡啶酮衍生物及其应用
AU2006232517A1 (en) * 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
US20090088574A1 (en) * 2005-12-21 2009-04-02 Eisai R&D Management Co., Ltd. Crystal of 1,2-dihydropyridine compound (type iv)
US7803818B2 (en) 2005-12-21 2010-09-28 Eisai R&D Management Co., Ltd. Amorphous form of 1,2-dihydropyridine compound
US7718807B2 (en) 2006-04-28 2010-05-18 Eisai R&D Management Co., Ltd. Salt of 1,2-dihydropyridine compound
CA2656057C (en) 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
WO2008111590A2 (en) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases
WO2008121074A1 (en) * 2007-03-29 2008-10-09 Agency For Science, Technology And Research Method of producing an optically active cyanohydrin derivative
WO2008139984A1 (en) * 2007-04-26 2008-11-20 Eisai R & D Management Co., Ltd. Cinnamide compounds for dementia
US20100179193A1 (en) * 2007-07-13 2010-07-15 Eisai R&D Management Co., Ltd AMPA Receptor Antagonists and Zonisamide for Neuropathic Pain
CA2690110A1 (en) * 2007-07-13 2009-01-22 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for neuropathic pain
US20100222354A1 (en) * 2007-07-13 2010-09-02 Eisai R & D Management Co., Ltd. AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
SG174214A1 (en) 2009-03-25 2011-10-28 Abbott Lab Antiviral compounds and uses thereof
ITMI20111952A1 (it) 2011-10-27 2013-04-28 Italiana Sint Spa Procedimento per la prepazione di 2-metossi-5-(piridin-2-il)piridina, un intermedio del perampanel
US9096574B2 (en) 2012-01-03 2015-08-04 Mapi Pharma Ltd. Polymorphs of perampanel
ITMI20121390A1 (it) * 2012-08-06 2014-02-07 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di acido 2-cianofenilboronico e suoi esteri, intermedi del perampanel o di e2040
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9695147B2 (en) 2013-07-25 2017-07-04 Teva Pharmaceuticals International Gmbh Process for the preparation of perampanel
CN104649962A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 吡仑帕奈倍半水合物化合物
CN103664756A (zh) * 2013-11-26 2014-03-26 苏州晶云药物科技有限公司 吡仑帕奈新晶型a及其制备方法
CN104706604A (zh) * 2013-12-12 2015-06-17 北京星昊医药股份有限公司 一种吡仑帕奈冻干口崩片及其制备方法
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CN105085382B (zh) * 2014-05-14 2019-10-18 江苏豪森药业集团有限公司 吡仑帕奈异构体晶型及其制备方法和用途
CN103980188B (zh) * 2014-05-30 2016-01-27 浙江永宁药业股份有限公司 一种吡仑帕奈的合成方法及其中间体和中间体的合成方法
WO2016132343A1 (en) 2015-02-17 2016-08-25 Mapi Pharma Ltd. Process and intermediates for the preparation of perampanel
WO2016147104A1 (en) * 2015-03-14 2016-09-22 Intas Pharmaceuticals Ltd. Novel process for the preparation of perampanel and its intermediates thereof
WO2016172333A1 (en) 2015-04-21 2016-10-27 Teva Pharmaceuticals International Gmbh A solid state form of perampanel
CN105287411A (zh) * 2015-09-22 2016-02-03 美吉斯制药(厦门)有限公司 一种吡仑帕奈分散片及其制备方法
CN105906557A (zh) * 2016-03-30 2016-08-31 北京万全德众医药生物技术有限公司 2-甲氧基-5-(吡啶-2-基)吡啶的一种合成方法
CN106389367B (zh) * 2016-11-16 2020-12-18 杭州朱养心药业有限公司 吡仑帕奈包衣片剂药物组合物
CN110028442B (zh) * 2018-01-11 2020-07-17 新发药业有限公司 一种吡仑帕奈的简便制备方法
KR20200132858A (ko) 2018-03-20 2020-11-25 에자이 알앤드디 매니지먼트 가부시키가이샤 간질 치료제
EP3560934A1 (en) 2018-04-26 2019-10-30 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure 2-cyanophenylboronic acid and esters thereof, intermediates of perampanel or of e2040
MA54460A (fr) 2018-12-14 2021-10-20 Eisai R&D Man Co Ltd Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine
KR102392825B1 (ko) 2020-02-18 2022-04-29 명인제약주식회사 2-(2-옥소-1-페닐-5-피리딘-2-일피리딘-3-일)벤조니트릴과 l-말릭산의 공결정 화합물 및 이의 제조 방법
WO2021240540A1 (en) 2020-05-26 2021-12-02 Celagenex Research (India) Pvt. Ltd. Novel synergistic nutritional compositions for treating seizures and chronic inflammatory diseases
CN114853666A (zh) * 2021-02-03 2022-08-05 北京万全德众医药生物技术有限公司 一种制备高纯度吡仑帕奈中间体的纯化方法
GR1010285B (el) * 2021-05-31 2022-08-24 Elpen Αε Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες περαμπανελης
KR102768044B1 (ko) * 2022-07-12 2025-02-17 이화여자대학교 산학협력단 연속 흐름 공정을 포함하는 페람파넬 유도체의 제조 방법
CN115745876B (zh) * 2022-11-01 2025-03-04 南京海纳医药科技股份有限公司 一种吡仑帕奈的制备方法
CN118415997B (zh) * 2024-07-04 2024-10-18 山东则正医药技术有限公司 一种吡仑帕奈细粒剂的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283761A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Novel pyridone derivative
JPS5531072A (en) 1979-07-30 1980-03-05 Rikagaku Kenkyusho Preparation of 2-pyridone compound
DE4221583A1 (de) * 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
IL109397A0 (en) 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HU219777B (hu) 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására
DK0784054T3 (da) 1994-09-27 2002-03-25 Yamanouchi Pharma Co Ltd 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister
EP0826671B1 (en) 1995-04-27 2004-12-29 Mitsubishi Pharma Corporation Heterocyclic amide compounds and medicinal use of the same
US5935551A (en) 1995-11-15 1999-08-10 California Institute Of Technology Synthesis of zeolites by hydrothermal reaction of zeolite P1
DE19604920A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
HU9600871D0 (en) 1996-04-04 1996-05-28 Gyogyszerkutato Intezet New 2,3-benzodiazepine derivatives
CN1103772C (zh) 1996-05-15 2003-03-26 辉瑞大药厂 新的2,3-二取代-4(3h)-喹唑啉酮类化合物
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
SK113299A3 (en) 1997-02-28 2001-05-10 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
GB9708945D0 (en) 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
AU1504599A (en) 1997-12-17 1999-07-05 Shionogi & Co., Ltd. Novel pyridine compounds
RU2000129671A (ru) * 1998-04-27 2004-02-20 Сантр Насьональ Де Ля Решерш Сьентифик (Fr) Производные 3-(амино- или аминоалкил) пиридинона и их применение для лечения болезней, связанных с ВИЧ
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
DE19835918A1 (de) 1998-08-07 2000-02-10 Dresden Arzneimittel Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung
ES2320973T3 (es) 2000-06-12 2009-06-01 EISAI R&D MANAGEMENT CO., LTD. Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos.
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP4208512B2 (ja) 2002-07-23 2009-01-14 株式会社クラレ 5−(2’−ピリジル)−2−ピリドン誘導体の製造方法

Also Published As

Publication number Publication date
SI1764361T1 (sl) 2013-07-31
JPWO2006004107A1 (ja) 2008-04-24
CA2570177A1 (en) 2006-01-12
KR20070028459A (ko) 2007-03-12
ATE547405T1 (de) 2012-03-15
KR101187218B1 (ko) 2012-10-02
NO20065754L (no) 2007-04-04
JP2012021029A (ja) 2012-02-02
TW200606144A (en) 2006-02-16
CA2561829A1 (en) 2006-01-12
IL180151A0 (en) 2007-06-03
CN104402807A (zh) 2015-03-11
CN101914057B (zh) 2012-07-04
MY148809A (en) 2013-05-31
AU2005258378B2 (en) 2011-04-28
IL180151A (en) 2012-01-31
US20100324297A1 (en) 2010-12-23
CN104402808A (zh) 2015-03-11
RU2323930C1 (ru) 2008-05-10
EP1772450A1 (en) 2007-04-11
EP1764361A1 (en) 2007-03-21
CN102382047A (zh) 2012-03-21
JO2832B1 (en) 2014-09-15
HK1104999A1 (en) 2008-02-01
CN101544599B (zh) 2012-06-06
BRPI0510254A (pt) 2007-10-23
AU2005258385B2 (en) 2009-11-05
TWI346660B (https=) 2011-08-11
US8304548B2 (en) 2012-11-06
MXPA06014458A (es) 2007-03-01
US9045426B2 (en) 2015-06-02
ME01520B (me) 2014-04-20
CY1114313T1 (el) 2016-08-31
US8772497B2 (en) 2014-07-08
CN101914057A (zh) 2010-12-15
US20070142640A1 (en) 2007-06-21
WO2006004100A1 (ja) 2006-01-12
EP1772450A4 (en) 2009-06-10
CA2570177C (en) 2012-11-20
IL180024A0 (en) 2007-05-15
PT1764361E (pt) 2013-04-23
IL180024A (en) 2011-09-27
NO339101B1 (no) 2016-11-14
BRPI0510254B1 (pt) 2019-10-29
JPWO2006004100A1 (ja) 2008-04-24
CN102382047B (zh) 2014-04-23
AU2005258385A1 (en) 2006-01-12
CN101544599A (zh) 2009-09-30
WO2006004100A8 (ja) 2006-02-23
EP2586771A3 (en) 2013-07-31
ZA200609274B (en) 2008-06-25
JP5030206B2 (ja) 2012-09-19
CN1942443B (zh) 2012-05-09
HRP20130363T1 (en) 2013-05-31
CN1984890A (zh) 2007-06-20
KR20070008617A (ko) 2007-01-17
BRPI0510254B8 (pt) 2021-05-25
EP2586771A2 (en) 2013-05-01
JP5419944B2 (ja) 2014-02-19
PL1764361T3 (pl) 2013-06-28
PL1772450T3 (pl) 2012-07-31
US20140142315A1 (en) 2014-05-22
EP1764361A4 (en) 2012-05-30
WO2006004107A1 (ja) 2006-01-12
EP1772450B1 (en) 2012-02-29
SI1772450T1 (sl) 2012-06-29
ES2404697T3 (es) 2013-05-28
EP1764361B1 (en) 2013-01-30
RS52752B (sr) 2013-08-30
CA2561829C (en) 2009-11-24
HK1102127A1 (en) 2007-11-09
KR100939743B1 (ko) 2010-02-04
AU2005258378A1 (en) 2006-01-12
NZ550720A (en) 2009-10-30
CN1942443A (zh) 2007-04-04

Similar Documents

Publication Publication Date Title
DK1764361T3 (da) Krystal af 1,2-dihydropyridinforbindelse og fremgangsmåde til fremstilling heraf
DK2090575T3 (da) Fremgangsmåder og mellemprodukter til fremstillingen af N4 phenylquinazolin-4-aminderivater
EA200701358A1 (ru) Кристаллические формы гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1h-3-бензазепина
DE602004017703D1 (de) Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus
DK1761522T3 (da) Forbindelser og fremgangsmåder til behandling af dyslipidæmi
DK1860101T3 (da) Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf
ATE530519T1 (de) Cyclobutylaminderivate
UA90720C2 (en) Heteroaroyl-substituted serine amides
DK1397294T3 (da) Fremgangsmåde og anlæg til fremstilling af kæder af i lommer lagte skruefjedre med drivmekanisme
DK1704146T3 (da) Stereoisomere forbindelser og fremgangsmåder til behandling af mave-tarm- og centralnervesystemlidelser
DK1694354T3 (da) Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
WO2004099197A3 (de) Substituierte oxyarene und deren verwendung zur bekämpfung von schädlingen
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE602004023529D1 (de) Regelung der Güte (Q) von Filtern
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
DK1599452T3 (da) 3- (2-phenyloxazol- 4-ylmethoxy) - cyclohexylmethoxyeddikesyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerosw
MX274842B (es) Procedimiento para la produccion de sales de (4,5-dihidroisoxazol- 3-il)tiocarboxamidina.
WO2004020416A3 (de) Substituierte pyridine oder pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als schädlingsbekämpfungsmittel
NO20050885L (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
NO20053431D0 (no) Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid.
EP1486497A4 (en) NEW PYRIDONE DERIVATIVE
WO2006021654A8 (fr) Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
NO20064410L (no) Fremgangsmate for fremstilling av tryptaseinhibitorer
PL373929A1 (pl) Sposób wytwarzania N-(5-amino-2-metylofenylo)-4-(3-pirydylo)-2-pirydynoaminy